Roche Fuzeon Dosing Convenience Is Challenge, Not Price – Physician Panel
Executive Summary
The dosing convenience of Roche's injectable HIV drug Fuzeon could be one marketing challenge for the company, physician panelists predicted during a Banc of America-sponsored healthcare forum in New York City Dec. 11
You may also be interested in...
Roche Fuzeon Phase IV Commitments Include Pneumonia Incidence Study
Roche's postmarketing commitments for Fuzeon include a study on the incidence of pneumonia in HIV patients treated with the antiretroviral
Roche Fuzeon Phase IV Commitments Include Pneumonia Incidence Study
Roche's postmarketing commitments for Fuzeon include a study on the incidence of pneumonia in HIV patients treated with the antiretroviral
Roche Fuzeon 2003 Production: 15,000-Patient Supply Plus 6-Month Cushion
Roche/Trimeris' 2003 production cap for Fuzeon includes doses for 12,000 to 15,000 patients, in addition to a six-month "safety supply," the companies said during a Dec. 18 analyst call